An Open Label, Randomised, Four-Period Crossover, Single Dose Study in Healthy Volunteers to Evaluate the Pharmacokinetics of FF/UMEC/VI Combination Administered at Dose Levels 100/62.5/25 mcg and 100/125/25 mcg and in Comparison With FF/VI (100/25 mcg) and UMEC/VI (62.5/25 mcg)
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Umeclidinium/vilanterol; Vilanterol/fluticasone furoate
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Jul 2013 New trial record